Primary Job Title President, CEO Primary Organization 
Veloxis
Location Denmark, Europe Regions European Union (EU), Nordic Countries, Scandinavia Gender Male
LinkedIn View on LinkedIn
Dr. Polvino is a pharmaceutical entrepreneur with more than 26 years of experience in the pharmaceutical and healthcare arena. Most recently, Dr. Polvino was president and chief executive officer of Veloxis Pharmaceuticals A/S (NASDAQ: VELO), a public biotechnology company that deploys proprietary formulation technology to develop and
commercialize innovative oral drug products. Prior to Veloxis, Dr. Polvino held positions at Helsinn Therapeutics (formerly Sapphire Therapeutics), where he also served as the company’s president and CEO. During his tenure at Helsinn, he advanced novel in-licensed, preclinical stage, new chemical entities into late-stage clinical development and registration in the supportive oncology space. Dr. Polvino has also held executive and senior level positions within drug development at Merck, Wyeth and Theravance. Dr. Polvino earned a medical degree from Rutgers Medical School and a B.S. in Biology from Boston College. He was also a fellow in clinical pharmacology at the National Institute of Health and trained in internal medicine at Massachusetts General Hospital.
